Takura

Takura is a Swedish private investment company that acts as an early-stage developer of biopharma companies, focusing on bringing novel cell and gene therapies into clinical practice. It founds, funds, and builds companies, transforming scientific ideas into products. The company has a portfolio focused on advanced cell therapies, including mesenchymal stromal cells (MSC) and tumor-infiltrating lymphocytes (TIL). Takura was a key early investor in Cellcolabs, a company specializing in the industrial production of MSCs, which it later spun off to its shareholders in 2023 to focus on even earlier-stage biopharma development.